N,N-dimethyl-N'-7H-pyrrolo[2,3-d]pyrimidin-4-yl-imidoformamide | 677008-35-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: N,N-dimethyl-N'-7H-pyrrolo[2,3-d]pyrimidin-4-yl-imidoformamide
• 英文别名: N,N-dimethyl-N'-7H-pyrrolo[2,3-d]pyrimidin-4-ylimidoformamide；N,N-dimethyl-N'-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)methanimidamide
• CAS: 677008-35-4
• 化学式: C₉H₁₁N₅
• 分子量: 189.22
• InChiKey: XSKAPJWEMJGQGS-UHFFFAOYSA-N

物化性质

• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-N'-7H-pyrrolo[2,3-d]pyrimidin-4-yl-imidoformamide 在 2,2'-联吡啶 、 copper diacetate 、 sodium carbonate 、 乙二胺 作用下， 以 乙醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 20.0h， 生成 7-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  一类含杂芳环炔基化合物及其制备方法和用途

  摘要：

  本发明涉及一类含杂芳环炔基化合物及其制备方法和用途，所述含杂芳环炔基化合物为式(I)的化合物，或其氘代化合物、药学上可接受的盐、溶剂化物、酯、酸、代谢物或前药。本发明所述的式(I)化合物具有对原发性KIT突变和耐药型KIT突变携带的肿瘤细胞具有强效的杀伤效果。#imgabs0#

  公开号：

  CN116730978A
• 作为产物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 4-氨基-7H-吡咯[2,3-d]嘧啶 以 N,N-二甲基甲酰胺 为溶剂， 以73%的产率得到N,N-dimethyl-N'-7H-pyrrolo[2,3-d]pyrimidin-4-yl-imidoformamide
  参考文献：
  名称：

  一类含杂芳环炔基化合物及其制备方法和用途

  摘要：

  本发明涉及一类含杂芳环炔基化合物及其制备方法和用途，所述含杂芳环炔基化合物为式(I)的化合物，或其氘代化合物、药学上可接受的盐、溶剂化物、酯、酸、代谢物或前药。本发明所述的式(I)化合物具有对原发性KIT突变和耐药型KIT突变携带的肿瘤细胞具有强效的杀伤效果。#imgabs0#

  公开号：

  CN116730978A

文献信息

• [EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 6-AMINO-7-DÉSAZA-PURINE, PROCÉDÉ POUR LES PRÉPARER ET LEUR UTILISATION COMME INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2014184069A1

  公开（公告）日：2014-11-20

  The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

  本发明涉及调节蛋白激酶活性的6-氨基-7-去氮嘌呤衍生物，因此在治疗由失调的蛋白激酶活性引起的疾病中特别有用，尤其是RET家族激酶。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用含有这些化合物的药物组合物治疗疾病的方法。
• PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：US20160166575A1

  公开（公告）日：2016-06-16

  The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions containing these compounds.

  本发明涉及6-氨基-7-去氮嘌呤衍生物，其调节蛋白激酶的活性，因此在治疗由失调的蛋白激酶活性引起的疾病，特别是RET家族激酶方面非常有用。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用含有这些化合物的药物组合物治疗疾病的方法。
• Determination of RNA Tertiary Structure by Electron Paramagnetic Resonance Spectroscopy (EPR)
  作者：Nelly Piton、Joachim W. Engels

  DOI：10.1081/ncn-120023107

  日期：2003.10

  Since the discovery of ribozymes in 1980, RNA is no longer considered only as a transporter of the genetic information but also as a participating molecule in each step of the gene expression. RNA can form complex three dimensional structures designed to perform specific functions. These structures are highly dependent on the presence of metal ions but few have been already solved. In the last few years the Electron Paramagnetic Resonance (EPR) spectroscopy has enabled a real improvement in the determination of proteins' conformation([1]) but few studies have been performed on nucleic acids.([2])Indeed EPR enables to gain structural (distances between 15 and 60Angstrom can be measured) and dynamic data (motions which occur on a timescale from millisecond to nanosecond can be analysed). Our aim is to test this method on the well known Hammerhead Ribozyme, whose X-ray structure has been entirely determined in 1994:31 it is composed of one core and three helices, whose orientation depends on the magnesium concentration. Besides the magnesium ions are involved in the mechanism of substrate's self-cleavage.